I tried four vibe-coding tools, including Cursor and Replit, with no coding background. Here's what worked (and what didn't).

An AI powerful enough to analyze DNA, file taxes, and grow tomato plants is being redesigned for everyday work, pointing ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive ...

We have two network cards on each PCs, that are connected with different networks. We are trying to publish and subscribe between such two PCs and would like to check for the duplication of messages.

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Vir Biotechnology (VIR). The reason why I want to go over this biotech next is because it is ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

OpenAI announced on Thursday it has acquired Software Applications, Inc., the makers of an AI-powered natural language interface for Mac computers called Sky. The software product, which had not been ...

Firefly Aerospace Inc. (NASDAQ:FLY) Q2 2025 Earnings Call Transcript September 23, 2025 Operator: Greetings. Welcome to the Firefly Aerospace Second Quarter 2025 Financial Results Conference Call.

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

(RTTNews) - Northrop Grumman Corp. (NOC), Thursday announced that it has committed $50 million to Firefly Aerospace to accelerate production of their jointly developed medium class launch vehicle, ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...